



GOG PARTNERS CONNECTION

A Quarterly Newsletter

From GOG Partners, A GOG Foundation Program

The GOG Foundation, Inc. has one mission:
Transforming the standard of care in gynecologic oncology

BUILDING THE FUTURE OF GYNECOLOGIC ONCOLOGY

A Message From The GOG Foundation's Education & Mentoring Committee

On behalf of the GOG Foundation, Inc. (GOG-F) Education and Mentoring Committee, we are proud to share a recent publication, "[Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: The GOG Foundation, Inc.'s Scholar Career Development Award and New Investigator Program](#)" published in the *International Journal of Gynecological Cancer*.



This publication highlights the five-year evaluation of our tiered investigator development programs and demonstrates the success of a structured framework of awards for workforce development. Building and sustaining a strong physician-scientist and clinical trialist workforce is critical to accomplish the GOG-F's mission to conduct transformative gynecologic oncology research that will positively impact patients.

Yet, the reality remains stark: the physician-scientist workforce in our field is critically underdeveloped. As of 2020, just 1.3% of U.S. physicians reported research as their primary professional activity. The challenge is further exacerbated by the persistent underfunding of gynecologic cancer research and early career development grants at the federal level. Physician-scientist and clinical-trialist leaders who can drive innovation, reduce disparities, and shape practice-changing clinical trials are vital to advance gynecologic oncology research. Recognizing the systemic shortfalls and challenges, the GOG-F convened a strategic summit in 2018 to define our future research and workforce priorities.

From that summit emerged a call to action: to create sustainable training pathways for clinical trialists equipped with the expertise needed to lead studies, navigate complex regulatory environments, and manage multidisciplinary research teams. In response, the GOG-F established the Education and Mentoring Committee with a clear mission—to educate our members, enhance competencies in trial design and translational science,

and, crucially, identify and elevate early- and mid-career investigators. This committee, originally chaired under the leadership of Drs. Ronald Alvarez and Angeles Alvarez Secord, created two key programs to strengthen the clinical trial workforce in gynecologic oncology. The New Investigator Program is a three-year award aimed at early-career clinicians interested in clinical trials, provides educational programming and travel support to facilitate their involvement with GOG-F and NRG Oncology. The Scholar Career Development Award is a five-year award supports mid-career investigators with 10% protected time, structured funded mentorship, and opportunities to lead and engage in clinical trial development, operations, and oversight.

During this initiative, Dr. Alvarez quoted, “We are planting the trees that will provide shade for generations to come.” Trees symbolized the power of growth and sustainability of a robust investigator workforce. A workforce that will ensure the ongoing vitality of our clinical trial infrastructure and provide lasting and meaningful contributions for our patients and broader oncology community for generations to come.



Today, we share the result of this purposeful cultivation. Collectively, these programs have demonstrated high levels of success based on tremendous academic productivity, clinical trial leadership, and subsequent grant funding. Participants have driven remarkable progress, authoring over 1,000 peer-reviewed publications, securing \$150.43 million in research funding, leading pivotal trials that have transformed standards of care, and enrolling over 3,100 participants into clinical trials.

These achievements are a testament not only to the talent and drive of our Scholars and New Investigators, but also to the effectiveness of structured, specialty-specific mentorship models that are both scalable and replicable. We are honored to follow in the footsteps of Dr. Ronald Alvarez, who led the Education and Mentoring Committee and championed the creation of a dedicated development framework for clinical trialists.



We would also like to express deep gratitude to Dr. Larry Copeland, who served as GOG-F President, and Dr. Robert Mannel, Senior Vice President and NRG Oncology Group Chair, at the time these awards were launched as well as Dr. Thomas Herzog, current President of GOG-F. Their combined support and belief in the importance of educational investment made it possible to implement and financially support these programs and achieve these successful outcomes today. In addition, the tireless efforts of Michelle Small, our Director of Education, whose behind-the-scenes coordination has made these programs not only functional but truly impactful. The financial impact of these programs is substantial and fully funded through the GOG-F, demonstrating ardent commitment to advancing clinical trials through sustained and strategic investment.

Identifying, mentoring, supporting, and retaining clinical trialists is more than an educational goal—it is essential for our patients, integral to the future of our organization, and fundamental to advance care in gynecologic oncology. The investment is substantial, but the return, measured in discoveries, leadership, and improved care for patients is priceless. GOG-F is committed to this effort fostering a robust and diverse research workforce to create the conditions for innovation, equity, and excellence in gynecologic cancer research, and lasting impacts on peoples' lives.

Our commitment is unwavering. The saplings are robust, and more trees will be planted to provide a wide canopy of shade for generations to come.

[Click here](#) to read the publication.

IDEA COMMITMENT & RESOURCES

Collaborating to make an Impact, Drive our mission to transform the standard of care in women's cancers forward, Empower physicians and patients to improve Access to clinical trials and tomorrow's drugs today.



Identifying and Breaking Barriers: Addressing Disparities in the Care of Patients with Gynecologic Cancers

Publication Highlights:

- An advisory board series was conducted to identify barriers and solutions to equitable health care in diverse populations.
- Barriers common to all populations included cost, transportation, lack of health literacy, and provider bias.
- Population-specific barriers were noted for each population, with the most barriers identified among LGBTQIA+ patients.
- Increased use of patient navigators was noted to be a solution that could reduce multiple barriers across all populations.

[Click here](#) to read the full publication.

Diversity and Inclusion in Clinical Trials

Join Dr. Janelle Darby, member of the SGO Clinical Trials Management/Concepts Subcommittee, as she interviews Drs. Evan Graboyes, Jeffrey Hines, and Bhavana Pothuri, the GOG-F Director of Clinical Trial Access, addressing continued efforts to improve inclusion of racially and ethnically diverse patients in clinical trials.

[Click here](#) to view the full presentation.

The GOG-F is grateful to the Society of Gynecologic Oncology for their partnership and allowing the GOG-F to reshare this content.

IDEA Commitment Education & Additional Resources

SPECIAL RECOGNITION



LEADERSHIP AWARD

WILLIAM T. CREASMAN, MD



**Thank you for your legacy of excellence
advancing the GOG Foundation's mission
to transform the standard of care.**

The GOG-F proudly honors Dr. William T. Creasman, a pioneering force in gynecologic oncology whose career has shaped the field and inspired generations of clinicians and researchers.

A founding member of the legacy Gynecologic Oncology Group (GOG), Dr. Creasman played a critical role in shaping the foundation's mission and clinical research infrastructure. His leadership in protocol development, quality control, and modality oversight helped establish rigorous standards that continue to guide GOG's work today. He was also a key advocate during the transition to NRG Oncology, ensuring the preservation of GOG's specialized focus on gynecologic cancers.

Beyond GOG, Dr. Creasman chaired the FIGO Gynecologic Cancer Committee for over a decade, influencing global cancer staging and treatment guidelines. His contributions to literature, including co-authoring Clinical Gynecologic Oncology, have become cornerstones in medical education.

Dr. Creasman's enduring commitment to patient care, research, and mentorship exemplifies the values of the GOG Foundation. We celebrate his legacy and thank him for his unwavering dedication to advancing gynecologic oncology.



Mary Sharp, is retiring from her role as Chief Financial Officer after 39 years of service.

She was born and raised in DC. Graduated from Bowie State University in 1981 with a degree in Accounting & was hired by ACOG in 1986 as Special Projects Administrator for the Gynecologic Oncology Group, moving on to become the Director of Finance for the GOG grant, managing the grant finances and acting as a liaison for activities with the Philadelphia office.

In 2002, Mary, as the appointed CFO, was instrumental in helping the Gynecologic Oncology Group apply for its 501(c)(3) status, later named The GOG Foundation, Inc. With this independence from ACOG she moved its finance and human resource activities to a Maryland location. Mary started the Maryland location with a staff of 3 employees, and it now has 15 employees.

In 2014, Mary and others spent over a year helping to develop NRG and transferring GOG's portion of the federal grant to the newly founded NRG, per federal requirements.

A few years prior to the NRG transition, she was instrumental in helping develop the GOG's Partners brand, program and activities. After 39 years of service, Mary will be retiring but is happy that the organization she has worked for and come to love, is in a good place financially.

in Gynecologic Oncology Award

Congratulations Bhavana Pothuri, MD, MS for receiving the 2025 Health Equity Awareness & Advocacy in Gynecologic Oncology Award during the SGO 2025 Annual Meeting in Seattle, Washington.



"I am deeply honored and humbled to receive the 2025 Health Equity Awareness and Advocacy in Gynecologic Oncology Award. This recognition strengthens my commitment to advancing diversity and health equity in gynecologic oncology, and I share it with the GOG-F and all those working alongside us to break down barriers and ensure inclusive, equitable care for all patients."

Please join us in welcoming our newest GOG Team Members!

- **William Dudley**
Clinical Trials Contract Attorney, Legal
- **LaTrenda Jamison**
Clinical Trials Project Manager, GOG Partners
- **Jessica Laird**
Intern, Business Development
- **Carolyn Majors**
Associate Director of Meetings, Business Development
- **Amy Neff**
Protocol Specialist, Clinical Trials Development
- **Heather Rush**
CME Specialist, Education/Finance
- **Kara Shumaker**
CME Compliance Coordinator, Education/Finance
- **Thomas Walsh**
Chief Financial Officer, The GOG-F

GOG FOUNDATION[®] Transforming the standard of care

GOG PARTNERS



Top Accruing Sites – 3 Year GOG Partners/NRG Combined Accrual

Name
The Ohio State University Comprehensive Cancer Center
University of Oklahoma Health Sciences Center
NYU Langone Medical Center - NYU Clinical Cancer Center - Womens Cancer Program*
Memorial Sloan Kettering Cancer Center
University of Virginia
Women & Infants Hospital
Women's Cancer Center of Nevada
Cleveland Clinic Foundation
Abington Memorial Hospital - Asplundh Cancer Pavilion/Thomas Jefferson
Georgia Regents/Augusta University
Froedtert and The Medical College of Wisconsin
University of Colorado Hospital - Anschutz Cancer Pavilion
The Blavatnik Family - Chelsea Medical Center at Mount Sinai
Washington University School of Medicine
Center of Hope
HonorHealth Research and Innovation Institute
Oklahoma Cancer Specialists and Research Institute, LLC
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
University of Rochester
Duke University Medical Center
University of California San Diego Moores Cancer Center
Virginia Commonwealth University (VCU) Massey Comprehensive Cancer Center
Yale University
MD Anderson Cancer Center
Texas Oncology - Fort Worth (DFW) - USO
Northwestern University
New Mexico Cancer Care Alliance/University of New Mexico Comprehensive Cancer Center
Levine Cancer Institute, Atrium Health (Carolinas Medical Center)
Rutgers Cancer Institute of NJ
University of Iowa Hospitals and Clinics
Maine Medical Center
UCLA Johnson Comprehensive Cancer Center
University of Washington Fred Hutchinson Cancer Center (FHCC)/Seattle Cancer Care Alliance
Western Pennsylvania Hospital/West Penn Hospital - Allegheny Health Network
University of Pennsylvania
Swedish Medical Center
Trials365, LLC

Name
University of Cincinnati
The University of Arizona Cancer Center
Huntsman Cancer Institute
University of Texas Southwestern Medical Center*
University of Chicago Medical Center
Baystate Medical Center
Weill Cornell Medicine - New York Presbyterian Hospital
University of Minnesota
University of Alabama at Birmingham
Oncology Associates of Oregon - Willamette Valley Cancer Institute and Research Center - USO
Advent Health Orlando
Endeavor Health (NorthShore University Health System)
University of Wisconsin
University of Nebraska Medical Center
Mount Sinai Medical Center
Lewis Cancer & Research Pavilion at St. Joseph's/Candler
University of Arkansas for Medical Sciences
University of Michigan
Cedars Sinai Medical Center
SUNY Upstate Medical University
Princess Margaret Cancer Centre
University of California, San Francisco*
McGill University - MUHC
Avera Cancer Institute
Womens Cancer Center/Kettering Cancer Center
Texas Oncology, P.A., San Antonio Medical Center - SCRI
Minnesota Oncology Hematology, PA - Maplewood - SCRI
University of Miami Miller School of Medicine-Sylvester Cancer Center
Northwell Health/Monter Cancer Center
Women's Cancer Care Associates, LLC
Sarasota County Public Hospital d/b/a Sarasota Memorial Hospital and Sarasota Memorial Health Care System
Good Samaritan Hospital
Karmanos Cancer Institute
Alaska Women's Cancer Care/Providence Alaska Medical Center
Providence Portland Medical Center
Texas Oncology - Central/South - SCRI
Medical University of South Carolina (Hollings Cancer Center)
Dana Farber Cancer Institute (DFCI)
Mayo Clinic Rochester

Name
Sunnybrook Odette Cancer Center
Louisiana State University Health Science Center
Magee Women's Hospital - UPMC
Sanford Health System
Stanford University
Hoag Memorial Hospital/Gynecologic Oncology Associates Inc.
Minnesota Oncology Hematology, P.A. Minneapolis - SCRI
Nebraska Methodist Hospital
City of Hope
Metro MMCORC
University Hospital Cleveland Medical Center/Case Western Reserve
Northwestern Medicine Warrenville
Texas Oncology - Gulf Coast (The Woodlands), Gynecologic Oncology - SCRI
Baptist Healthcare System d/b/a Baptist Health Research (Lexington)
Legacy Good Samaritan Medical Center
Wake Forest University
Moffitt Cancer Center
Roswell Park Cancer Institute
University of California, Davis Comprehensive Cancer Center
Parkview Research Center
ProMedica Flower Hospital
TMC HealthCare/TMC Health Cancer Center (prev Arizona Oncology Associates, PC - HOPE)
Texas Oncology - Northeast Texas (Tyler) - USO
Miami Valley Hospital South
St. Elizabeth Healthcare
John Muir Medical Center
Mercy Hospital of St. Louis
Northside Hospital
Greater Baltimore Medical Center
Oregon Health and Science University (OHSU)
Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center (SKCCC)
University of Massachusetts Memorial Medical Center
Virginia Oncology Associates - SCRI
Compass Oncology Rose Quarter (Northwest Cancer Specialists, P.C. - SCRI)
CHUM (Centre Hospitalier de l'Université de Montréal) - University of Montreal
Winship Cancer Institute at Emory University
Name
Penn Medicine Lancaster General Hospital
Good Samaritan University Hospital (Catholic Health)

CLINICAL TRIALS

The GOG-P Program is currently recruiting for 24 clinical trials

- 11 Ovary
- 4 Cervix
- 9 Endometrium

To search active trials visit our website by clicking Clinical Trials button below.



[Clinical Trials](#)

IN THE NEWS

The GOG Foundation and EVA/LACOG Partnership: A Collaborative Strategic Alliance for Clinical Trial Execution Publication

The collaborative efforts between GOG and LACOG are aimed at advancing clinical oncology research through strategic global partnerships, particularly related to the conduct of clinical trials. Herein, we provide the framework of this relationship addressing key operational components including establishing a shared Publication Policy. In addition, this initiative seeks to standardize contributions, recognize authorship fairly, and ensure compliance with agreed protocols. Emphasis is placed on critical practices like study design, data interpretation, manuscript development, and intellectual review. The Policy considers the roles of individual scientists, institutional sponsors, and contributors while ensuring transparency and authenticity in scientific communication. This collaborative approach underscores the importance of collective expertise in addressing global challenges in oncology and fostering innovation through multi-institutional cooperation. The manuscript outlines the processes for critical review, approval, and publication, ensuring credibility in the dissemination of scientific findings to the community. These frameworks aim to promote inclusivity, equitable representation, and the advancement of oncology knowledge.

[Click here](#) to read the full publication.

ENGOT-ov-60 | GOG-3052 | RAMP 201 Press Release

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

BOSTON—(BUSINESS WIRE)—May 8, 2025— Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy.

[Click here](#) to read full press release.


AVMAPKI™ FAKZYNJA™ CO-PACK
 (avutometinib capsules; defactinib tablets) 0.8mg/200mg

NOW APPROVED
[LEARN MORE >](#)


AF-US-2025-0018

PHILANTHROPY

The New Horizons Gynecologic Cancer Research Fund is the philanthropic arm for the GOG-F. Donations allow the GOG-F to enrich efforts to develop and deliver essential research tools needed to further clinical trial development and translational research programs. Donations from individuals, corporations and foundations directly fund the GOG-F educational and research initiatives.



Together, we collaborate with industry to find new treatments, more effective prevention while promoting excellence in scientific research in the field of gynecologic malignancies.

Your Gift Makes a Difference!

With a focus on clinical trials, scientific research and development, we are closer to a cure. Each donation received will go directly to provide:

- Much-needed resources to effectively work towards the prevention and treatment of gynecologic malignancies
- Accessible research funding
- Ability to mentor New Investigators through fellowship awards
- Opportunity to raise public awareness through education and research
- Translational medicine initiatives across the disease committees

You may donate in your own name, your business' name, "In Memory of" or a donation in the name of a specific person you would like to recognize. All donations are tax deductible. The GOG-F Federal Tax ID# 03-0466352.

[Support Our Mission](#)

GOG 2025 INDUSTRY SPONSORS

The GOG-F and GOG Partners (GOG-P) would like to thank our Year-Round Sponsors for their support of our mission to transform the standard of care in gynecologic oncology.

EXECUTIVE PLATINUM SPONSORS



PLATINUM SPONSORS



GOLD SPONSORS

SILVER SPONSORS



ON DEMAND EDUCATION

The GOG Highlight Reel - July 2025

The GOG Highlight Reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course takes a deep dive into clinical trials for gynecologic malignancies, offering insights on recent data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians to comprehend the evolving treatment landscape, including understanding available trials in progress.

Participants will receive a synthesis of recent studies and explore key components of clinical trials, gaining essential knowledge for research in these malignancies. Dynamic discussions analyze emerging approved therapies and investigational agents, providing insights into current (as well as future) advancements. Join us for a journey through clinical trials in ovarian, endometrial and cervical cancers, gaining the analytical skills to navigate the latest oncology research and clinical care confidently.

[Click here](#) to view the recording and presentation slides.



Beyond ADCs: Exploring Novel Therapeutic Opportunities in Platinum Resistant Ovarian Cancer

The GOG-F and GOG-P welcome gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to view the **Beyond ADCs: Exploring Novel Therapeutic Opportunities in Platinum Resistant Ovarian Cancer**, an Industry Supported Symposium that was presented at the WAGO 2025 Annual Meeting on Friday, June 20, 2025.

This educational symposium will focus on innovative and emerging treatment options for patients with advanced, platinum-resistant high-grade epithelial ovarian cancer. While ADCs have transformed the landscape, the conversation is now evolving beyond these therapies. This



session will explore new and recently approved treatment opportunities, including novel mechanisms of action and strategic therapeutic combinations. Faculty will critically examine recent clinical trial data, taking a deeper look at progression-free survival (PFS) and overall survival (OS) curves, and how to interpret these metrics in a clinically meaningful way. Through expert insights and collaborative dialogue, attendees will be better equipped to apply data-driven strategies to improve patient outcomes.

[Click here](#) to view the recording and presentation slides.

The GOG Foundation, Inc. is grateful for our commercial supporter for this symposium: Corcept Therapeutics

UPCOMING INDUSTRY MEETINGS

ESMO 2025 Congress

Save the date for ESMO 2025, taking place in **Berlin, Germany 17-21 October 2025**.

The ESMO Congress is a highly influential global oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.

ESMO 2025 will be a place where groundbreaking discoveries, cutting-edge treatments and a collaborative approach converge to shape the future of cancer care. You will be able to learn from internationally renowned experts, engage in thought-provoking discussions and connect with fellow oncology professionals that are driving advancements in diagnosis, treatment and survivorship.

[Click here](#) for more information on the meeting.



GCIG Autumn 2025 Meeting

The GCIG Autumn 2025 meeting will be held **October 15 and 16, 2025** (prior to ESMO 17 Oct 2025-21 Oct 2025) in **Berlin, Germany at Kaiserin Friedrich-Stiftung** (Robert-Koch-Platz 7 in 10115 Berlin).

[Click here](#) for more information on the GCIG Autumn Meeting.



IGCS 2025 Annual Global Meeting

You are invited to the 2025 Annual Global Meeting of the International Gynecologic Cancer Society, which will be held at Century City Conference Centre in **Cape Town, South Africa from November 5-7, 2025**.

The IGCS Meeting is a platform for exchanging insights, sharing research findings, and discussing best practices. It's an opportunity to build professional networks, foster collaborations, and learn from some of the brightest minds in the field. Don't miss the chance to be part of this global community striving to make a difference in the lives of women affected by gynecologic cancers!

[Click here](#) for more information on the IGCS 2025 Annual Global Meeting!





GOG Foundation Inc. | Four Penn Center 1600 JFK Blvd. Suite 1020 | Philadelphia, PA
19103 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!